Merck Stock Plummets 4.72% Amid Recall and Mixed Trial Results Ranking 38th in Trading Volume

On May 13, 2025, Merck & Co., Inc. (MRK) experienced a significant decline of 4.72%, with a trading volume of $1.762 billion, ranking 38th in the day's stock market activity.

Merck's stock price dropped sharply due to the company's announcement of a recall of its popular diabetes drug, Januvia. The recall was initiated after reports of potential contamination in some batches of the medication. This news has raised concerns among investors about the company's quality control measures and the potential impact on its revenue from diabetes treatments.

Additionally, Merck's stock was further pressured by the release of a clinical trial update for its experimental cancer drug, MK-3475. The trial results, which were released earlier this week, showed mixed outcomes, with some patients experiencing significant improvements while others showed no response. This uncertainty has led to a sell-off in Merck's shares as investors await more definitive data from ongoing studies.

Despite these setbacks, Merck remains a leading player in the pharmaceutical industry, with a strong portfolio of drugs and a robust pipeline of new treatments in development. The company's long-term prospects are still viewed positively by many analysts, who believe that Merck's innovative approach to drug discovery will continue to drive growth in the years to come.